The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...
The Louisiana Department of Health noted yesterday that a 65-year-old hospital patient had died due to bird flu.
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...
CNBC on MSN10d
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billionShares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of ...
Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in acute respiratory illness due to higher rates of seasonal influenza ...
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback